Luo M, Liu RN, He ZM, Liang QF, Huang FL. Diagnosis and treatment of metachronous multiple primary carcinoma: A case report and review of literature. World J Clin Oncol 2025; 16(5): 105444 [DOI: 10.5306/wjco.v16.i5.105444]
Corresponding Author of This Article
Feng-Ling Huang, Chief Physician, Department of Pharmacology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, No. 10 Huadong Road, Nanning 530000, Guangxi Zhuang Autonomous Region, China. 15676639131@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. May 24, 2025; 16(5): 105444 Published online May 24, 2025. doi: 10.5306/wjco.v16.i5.105444
Diagnosis and treatment of metachronous multiple primary carcinoma: A case report and review of literature
Min Luo, Rui-Na Liu, Zhen-Mei He, Qian-Fu Liang, Feng-Ling Huang
Min Luo, Rui-Na Liu, Zhen-Mei He, Feng-Ling Huang, Department of Pharmacology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530000, Guangxi Zhuang Autonomous Region, China
Qian-Fu Liang, Department of Radiotherapy, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530000, Guangxi Zhuang Autonomous Region, China
Co-first authors: Min Luo and Rui-Na Liu.
Author contributions: Liang QF designed the research and the treatment regimen; Luo M and He ZM analyzed the data and follow up with the patient and organize information; Liu RN and Huang FL performed the research; Luo M prepared the first draft of the manuscript and responsible for data re-analysis and re-interpretation; Liu RN responsible for figure plotting, comprehensive literature search, preparation and submission of the current version of the manuscript and thus qualified as the co-first authors of the paper; Huang FL have played important and indispensable roles in the experimental design, data interpretation and manuscript preparation as the corresponding authors; All authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read CARE Checklist (2016), and the manuscript was prepared and revised according to CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Feng-Ling Huang, Chief Physician, Department of Pharmacology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, No. 10 Huadong Road, Nanning 530000, Guangxi Zhuang Autonomous Region, China. 15676639131@163.com
Received: January 23, 2025 Revised: February 27, 2025 Accepted: March 24, 2025 Published online: May 24, 2025 Processing time: 116 Days and 23.2 Hours
Abstract
BACKGROUND
Multiple primary carcinoma (MPC) refers to two or more types of primary malignant tumors occurring simultaneously or sequentially in the same patient. Breast cancer is one of the most common malignant tumors affecting women. On the other hand, diffuse large B-cell lymphoma (DLBCL) is the most frequent form of non-Hodgkin’s lymphoma (NHL). In clinical practice, the simultaneous existence of metachronous primary breast cancer and lymphoma is rare. In this case, we highlight the significance of multidisciplinary management and advanced imaging techniques in the early identification and treatment of MPC cases.
CASE SUMMARY
In this study, we report a case of a 40-year-old female who was diagnosed with invasive ductal carcinoma of the breast (T3N1M0 stage IIIA LuminalB type) as the first primary cancer and DLBCL (stage IIIA) as the second primary cancer. The patient underwent the modified radical mastectomy for left breast cancer and received Rituximab, cyclophospha-mide, hydroxydaunorubicin, Oncovin (vincristine) and prednisolone regimen chemotherapy treatment for DLBCL. As of now, the patient is in stable condition. The successful diagnosis of the present patient highlights the need for multidisciplinary management and adoption of advanced imaging techniques to identify the second primary cancer, especially NHL.
CONCLUSION
Accurate diagnosis and management of metachronous MPC requires an interdisciplinary team and selection of an appropriate treatment plan.
Core Tip: We report a case of a 40-year-old female diagnosed with invasive ductal carcinoma of the breast (T3N1M0 stage IIIA LuminalB type) as the first primary cancer and diffuse large B-cell lymphoma (DLBCL) (stage IIIA) as the second primary cancer. A modified radical mastectomy was selected for the treatment of left breast cancer and Rituximab, cyclophospha-mide, hydroxydaunorubicin, Oncovin (vincristine) and prednisolone regimen chemotherapy treatment to control DLBCL. At the last follow-up, the patient is in stable condition. In clinical practice, the simultaneous existence of metachronous primary breast cancer and lymphoma is rare. This case underscores the need for a multidisciplinary management approach and the adoption of advanced imaging techniques to facilitate early identification and treatment of rare multiple primary carcinoma cases.
